HIF1A and hepatocellular carcinoma: The inclusion of monitoring of the changes in serum HIF-1α and VEGF levels or HIF-1α and VEGF protein expression in tumor tissues after TACE of HCC patients as part of the efficacy evaluation criteria has enhanced the evaluation of HCC treatment.